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Executive Summary  
Antibiotic resistance – as governments,2 leading 
medical3 and public health organizations around 
the world now agree4,5 – is one of the most serious 
public health crises today.  
 
Before the discovery of antibiotics, patients with 
routine bacterial infections often died.  Without 
urgent action, that reality is likely to return as 
infections that are no longer treatable with today’s 
antibiotics continue to increase. At the same 
time, new antibiotics are proving challenging to 
develop.6 Over the last several decades, only two 
new classes of antibiotics have been developed and 
brought to market.7,8 Additionally, doubts have 
been raised about whether laws recently passed 
by the U.S. Congress granting financial rewards to 
pharmaceutical companies will actually help bring 
antibiotics to market that are both novel and more 
effective than existing drugs.9,10 Even if development 
work on new medicines were to begin today and 
eventually succeed, experience suggests that their 
availability for treating patients would be at least a 
decade away. 
 
Antibiotic use in people and in food animal 
production are important drivers of antibiotic 
resistance.11,12,13,14,15,16 The World Health 
Organization (WHO)17, United Nations18, European 
Medicines Agency19, and the Centers for Disease 
Control and Prevention (CDC)20 agree on the 
need to optimize use of antibiotics in both people 
and animals. Until we become better stewards of 
antibiotics, both in human medicine and in livestock 
production, these life-saving drugs will continue 
to become less effective, and the effectiveness of 
any antibiotics developed in the future will be at 
constant risk.  
 
 
 
 
 
 
The 2015 U.S. National Action Plan to Combat 
Antibiotic-Resistant Bacteria (CARB) focuses on 
curbing inappropriate antibiotic use in hospitals and 
clinic settings and has measurable reduction goals. 
However, the plan to curtail antibiotic use in food 
animal production is narrower in scope, mainly 
addressing the limited phase-out of antibiotics 
in animal feed or water for growth promotion 
purposes. This is problematic given that about 70% 
of medically important antibiotics21 sold in the U.S. 
(i.e. those identical or belonging to the same class 
as antibiotics used in human medicine) are sold 
for use in food-producing animals, not people.22 
Furthermore, the U.S. ranks second globally among 
users of antibiotics in food animal production, 
accounting for roughly 13% of the world’s total.23 
 
The imperative of this Commission is to keep 
existing antibiotics working and effective for as 
long as possible. We came together, as antibiotic 
resistance experts from the fields of infectious 
diseases, microbiology, veterinary and human 
medicine, to craft this Roadmap for how U.S. policy 
can and should better address the contribution 
to antibiotic resistance from antibiotic use in 
food animal production. We make specific policy 
recommendations in three key areas: decreasing 
antibiotic use, monitoring antibiotic use, and 
surveilling antibiotic resistance.  
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Summary of Roadmap Recommendations*
 
A.   Decreasing Livestock Use of Medically Important Antibiotics 
 
 1.   Set targets for reducing antibiotic use. 
 2.   Phase out routine or programed use of medically important antibiotics. 
 3.   Reduce the need for antibiotics by adopting non-antibiotic best practices, and by innovating      
       new technologies, to maintain animal health and prevent disease. 
 4.   Eliminate antibiotic use where efficacy can no longer be demonstrated. 
 5.   Prioritize the use in veterinary practice of antibiotics that the WHO does not categorize as  
       “critically important” for human medicine, such that: 
  A.   Antibiotics in the “Critically important” category are only used to treat animals  
        sick with a specific bacterial disease. Use of the subset of critically important   
        antibiotics the WHO refers to as “highest priority” also should require testing that  
        confirms the bacterium involved is not susceptible to other antibiotics. 
  B.   Do not approve for food and animal use any “critically important” antibiotics,  
        such as carbapenems, that are not currently FDA-approved for this purpose; 
 6.   Bolster veterinary oversight of antibiotic use with other safeguards. 
 
B.   Monitoring Antibiotic Use to Reduce Antibiotic Resistance 
 
 7.   Develop a system for collecting detailed, comprehensive data on actual antibiotic use,   
       and collect essential data. 
 8.   Coordinate with and learn from the other countries in developing a comprehensive   
       data collection system. 
 9.   Adopt a metric for reporting data on antibiotic sales or use that better allows trends to   
       be identified, explained and compared. 
 
C.   Enhancing Surveillance and Data Integration to Inform Antibiotic Use Policy 
 
 10.   Integrate available data into a single, comprehensive report. 
 11.   Improve surveillance to detect new and emerging resistance threats. 
  A.   Expand surveillance for emerging resistance using next generation sequencing  
        technology. 
  B.   Expand surveillance for important emerging pathogens, 
  C.   Pilot test approaches that comprehensively detect resistance in all bacteria in a  
        sample. 
  D.   Expand surveillance at the state level. 
 
 
* Note:  The numbering of the recommendations is not meant to connote any particular prioritization.
The following report fleshes out these recommendations and the rationale for each. 
Many of the recommendations draw upon successful models already implemented in 
Denmark and the Netherlands, two European countries with robust livestock sectors, 
comparable in size to that found in some of the most important livestock-producing 
states in the U.S.  Antibiotic use in food animal production in both countries has been 
markedly reduced, and has been generally accompanied by lowered or plateaued levels 
of resistant bacteria on animals and in meat, and sometimes in human populations. 24 25 26 
27 28 29 30                                    
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The Antibiotic Resistance Threat And Its Context
For a rising number of life-threatening infections, we have almost run out of safe, 
dependable and effective antibiotics that will treat them.31,32 The CDC conservatively 
estimates that 23,000 Americans die each year of antibiotic-resistant infections.33 Actual 
deaths, some experts say, may be four times higher.34 Predictions are that the global toll 
from a select number of resistant infections, estimated currently at 700,000 deaths per 
year, will rise to 10 million annually by 2050, surpassing deaths from cancer.35  
Many of the 2 million Americans who suffer from antibiotic-resistant infections each 
year have prolonged illness. Even recovered patients can be left disabled, disfigured or 
with permanent pain. Beyond its human costs, the antibiotic resistance epidemic poses 
an emerging threat to national and economic security. 36 Drug-resistant infections are 
estimated to cost more than $55 billion each year in extra U.S. medical costs (because 
of use of more expensive antibiotics, and longer and more intensive hospitalizations) 
and lost productivity.37  
Doctors often recommend procedures that can be complicated by infections, including 
joint replacements and chemotherapy, dialysis and Cesarean delivery, confident 
that there will be an antibiotic available if needed. Raising poultry, pigs and cattle 
successfully also depends on having antibiotics that work on sick animals. But this 
reliance on what are now the cornerstones of modern medicine could be in jeopardy. 
Without stronger action today, physicians and veterinarians face a future with less 
effective antibiotics, where their treatment of patients and animals may need to be 
substantially reconsidered. 
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Why This Roadmap Focuses on 
Medically Important Antibiotic Use in 
Agriculture 
 
Antibiotics are often necessary to treat sick patients 
and animals. But all uses of antibiotics even the 
most prudent can contribute to resistance. More 
specifically, exposing bacteria to antibiotics can 
spur resistance to emerge, be selected for, and then 
spread; that’s as true for bacteria in animals as it 
is for bacteria in people.38  The solution is not to 
avoid using antibiotics completely but rather to use 
them appropriately and only when necessary as 
the discoverer of the first antibiotic (penicillin), Sir 
Alexander Fleming, acknowledged more than seven 
decades ago.39  
 
This Commission believes the antibiotic resistance 
crisis cannot be resolved by only addressing 
antibiotic use in people, given the extensive use 
of the drugs in food animal production. As the  
CDC stated unequivocally in 2013: “Scientists 
around the world have provided strong evidence 
that antibiotic use in food producing animals can 
harm public health....”40 Poultry and livestock 
production accounts for about 70% of the medically 
important antibiotics (i.e. those in the same classes 
of antibiotics as those used in human medicine) 
sold in the U.S.41 In 2015, the latest year for 
which data are publicly available, this translates 
to 21,389,200 pounds of medically important 
antibiotic active ingredient sold for use in food-
producing animals.42,43 These include critically 
important antibiotics that the WHO considers to 
be the highest priority for human medicine, such 
as macrolides, fluoroquinolones and 3rd generation 
cephalosporins.  Compared to the rest of the 
developed world, as we later discuss, the U.S. is 
among the most intensive users of antibiotics in 
food animal production. Yet, as we discuss further, 
the U.S. National Action Plan for Combating 
Antibiotic-Resistant Bacteria (CARB) proposes 
concrete and measurable goals for curbing 
inappropriate antibiotic use in human medicine, but 
fails to set equivalent, numeric goals for reducing 
antibiotics used in food animal production.44 
 
A One Health Perspective 
 
Experts agree that the 21st century crisis of 
antibiotic resistance is a “One Health” issue.45,46 One 
Health is a public health concept recognizing that 
the health of people, animals and the environments 
in which they co-exist ‒ including the bacterial 
ecosystem are interconnected.47,48 Underscoring the 
importance of a One Health approach is the fact 
that scientists estimate “6 out of every 10 infectious 
diseases in people are spread from animals49”, as 
well as a recent study suggesting that at least some 
outbreaks of “livestock-associated” MRSA may 
stem from an initial introduction of that MRSA 
from people onto farms.50  The Danish Integrated 
Antimicrobial Resistance Monitoring and Research 
Programme (DANMAP) reiterates this approach: 
 
“DANMAP was developed making the most of a 
collaborative spirit between stakeholders and with a 
common understanding of [antimicrobial resistance] 
as a serious health threat requiring a One Health 
approach to counter - because humans, foods 
and animals constitute overlapping reservoirs of 
antimicrobial resistance.” 
One Health also describes a more integrated, 
interdisciplinary approach to tackling infectious 
disease threats to global health, involving 
microbiologists, ecologists and epidemiologists, 
physicians and veterinarians. This Commission 
has taken a One Health approach as reflected 
by its make-up, as well as in its conclusions and 
recommendations.  A One Health understanding 
underlies our shared sense that the antibiotic 
resistance crisis, whether in animal or human 
settings, is largely a “numbers game” the higher the 
use, the more resistance can emerge and spread ‒ 
which Box A explains in greater detail.  
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A half century of science, and hundreds of individual studies and reviews, support the idea that 
antibiotic resistance is a numbers game; in short, the risk for emergence and enrichment of 
antibiotic-resistant bacteria goes up with each person or animal that is treated or exposed to those 
drugs.51,52,53,54,55,56 Many scientific reviews, by renowned experts, have concluded that the existing 
body of evidence justifies stronger action to reduce antibiotic use in both human and animal 
settings. 57,58,59, 60,61,62  Our goal was not to duplicate these reviews, but instead to generate consensus 
recommendations, based upon the existing body of science, for policies and practices that will help 
curtail the unnecessary use of antibiotics in food animal production.   
 
–  
The greater the quantity of antibiotics used, the more resistance will emerge and 
spread.63,64,65  
 
The greater the number of individuals (human or animal) that are given antibiotics, 
the more bacteria are exposed, and the greater the likelihood resistance will emerge 
and spread.66,67 
 
The longer the duration of antibiotic use, the longer the period of time over which 
resistance can emerge and spread.68,69,70,71  
 
Editorial Note from the Commission: While exceptions may exist, these observations around 
antibiotic use and its impact on resistance hold true more often than not.
Box A:  One Health: Factors That Can Contribute to the Spread of Antibiotic Resistance
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Roadmap Recommendations for U.S. Policy  
on Use of Medically Important Antibiotics in 
Food Production 
 
In March 2015, the Obama Administration released the National Action Plan to 
Combat Antibiotic-Resistant Bacteria (CARB).72 It was presented as a guiding 
document to coordinate and map federal efforts to address antibiotic resistance, and 
ultimately preserve the future efficacy of antibiotics.  
 
CARB establishes five national goals to better understand, track and reduce antibiotic 
use, each of them accompanied by milestones and outcomes to be achieved by 2020. 
However, comprehensive goals and milestones to better track, understand and reduce 
antibiotic use in human settings are not mirrored by similarly comprehensive goals 
around antibiotic use in the production of livestock and poultry. Regarding antibiotic 
use in food animal settings, CARB largely defers to the FDA, the federal agency 
responsible for regulating these uses. As laid out in the following sections, however, there 
are serious shortcomings to the FDA’s approach. We strongly question whether current 
FDA efforts will lead to significant reductions in antibiotic use in food producing 
animals, and consequently succeed at reducing the spread of antibiotic resistance.  
 
To address these shortcomings, the Roadmap makes policy recommendations in 
three key areas: decreasing antibiotic use, monitoring antibiotic use, and surveilling 
antibiotic resistance. These recommendations are largely aimed at both federal and state 
policymakers, but also go beyond government policy. For example, Appendix A offers 
tools that medical professionals can use to help address livestock overuse of antibiotics 
and Appendix C includes recommendations for universities, hospitals, and other buyers 
of meat and poultry to use in procuring products.
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A.  Decreasing Livestock Use of Medically 
Important Antibiotics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is the Commission’s shared sense that the statements in Box A (page 7) capture 
important connections between antibiotic use and antibiotic resistance. They lead in 
turn to the following general priorities for policy action, which are applicable not only 
to the U.S. but also worldwide.  
 
Priority #1:  Ensure antibiotics are used only when necessary and effective, and when 
non-antibiotic alternatives are unavailable, so as to reduce overall exposure of bacteria to 
antibiotics (see Box B), and therefore the emergence and spread of resistance. 
 
 A)    When directed by a veterinarian, antibiotics should be used to treat  
  sick food-producing animals or those that have been exposed to an  
  animal with diagnosed disease. 
 
 B)    Antibiotics should not substitute for good animal management   
  practices. 
 
Priority #2:  Reduce the sale and use of medically important antibiotics, putting the 
highest priority on those deemed of greatest importance to human medicine. 
 
Priority #3:  Administer antibiotics for the shortest time period (duration) necessary. 
 
While equally relevant in human medicine, these priorities are framed in terms of food 
animal production because that is the focus of this report. These general priorities guide 
our later recommendations for urgently needed changes to U.S. policy and practice. 
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Bacteria can become resistant simply by errors being made as their DNA is copied, something that occurs 
each time bacteria reproduce.  They also can become resistant by picking up resistance genes from other 
bacteria. Using an antibiotic allows resistant bacteria that can withstand the antibiotic to survive and 
multiply. Other bacteria then can acquire resistance genes from these already-resistant bacteria. Because the 
gut harbors billions of bacteria – in food-producing animals, as well as in people – it can be a hot spot for 
exchange of resistance genes, including those acquired through the food supply.73,74,75,76 
 
A plasmid is a small unit of DNA that can carry multiple resistance genes. Plasmids also are easily shared 
among bacteria in human and animal guts. Non-resistant bacteria that are easily treatable with antibiotics 
can become resistant to many antibiotics in an instant by picking up one of these plasmids.77 Plasmids often 
carry genes that code simultaneously for resistance to both older and newer antibiotics, so that even when 
people or animals are exposed to or treated with older or less important antibiotics, it still can fuel growth of 
bacteria that are resistant to newer (often, more medically important) antibiotics. This underscores the need 
to thoughtfully use all antibiotics – new or old, and human or not.  
 
 
 
Use of Medically Important Antibiotics in Livestock  
 
It is estimated that the U.S. is the second highest user of antibiotics in food animal production, with 13% 
of the global total, behind China at 23%.78  The U.S. is one of the largest producers and exporters of meat 
and poultry, globally, but also stands out compared to many other major livestock-producing countries in 
terms of its consumption of antibiotics per unit of meat produced (See Figure 1).  As incomes rise in many 
developing countries, along with their demand for animal-based proteins, and more antibiotic-intensive 
methods for raising food-producing animals are adopted by them, it’s projected that their share of global 
antibiotics consumption also will rise.79
 
The Review on Antimicrobial Resistance, commissioned by the UK Prime Minister in 2014, compared 
agricultural antibiotic use in European Union nations with use in other developed countries, such as 
Australia, New Zealand and the U.S. Antibiotic use figures do not include ionophores or oligosaccharides.  
At about 180 mg/kg, the estimated intensity of antibiotic use in the U.S. (measured as milligrams of 
antibiotic active ingredient per kilogram of meat produced) is multiple times higher than countries such as 
Australia, Denmark, and the Netherlands, while roughly commensurate with others, such as Germany and 
Portugal.80  
 
 
 
 
Box B: Exposing Bacteria to Antibiotics Raises Risk for Resistance
Combating Antibiotic Resistance:  
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Figure 1:  Agricultural antimicrobial use (in mg/kg of animal body weight) in 25 EU/EEA countries, 
Australia, New Zealand and the U.S.81 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Work to dramatically reduce use of antibiotics in food-producing animals in the Netherlands serves as a good 
case study for the U.S. As recently as 2008, the Netherlands used antibiotics about as intensively as the U.S. 
does now. However, between 2009 and 2016, the use of antibiotics in Dutch livestock was reduced by more 
than 64%, after adoption of the policies and approaches described in Appendix E.82 Despite these changes, 
farmers maintained or increased their profits and levels of production, while the number of resistant bacteria 
in livestock were reduced significantly.83,84  These comparisons strongly suggest similar reductions also could 
be achieved in the U.S., if equivalent leadership were exerted, and policy changes were adopted. 
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Antibiotics routinely administered en masse – even when under veterinary supervision – raise additional 
concerns. Approximately 95% of the medically important antibiotics approved for use in U.S. food-
producing animals by volume are sold as additives to animal feed or water, to be administered to groups 
rather than to individual animals.85,86 Mass administration to flocks or herds was the typical route of delivery 
for medically important antibiotics given for growth promotion (now illegal in the U.S.), but it continues 
to be the primary way antibiotics are administered for routine disease prevention purposes.  When more 
animals, and therefore more bacteria, are exposed to antibiotics it elevates the risk that resistance will develop 
and spread.  
Feed or water-administered antibiotics are often labeled to allow for use over a prolonged period of time. 
About one-third of the medically important antibiotics still allowed for use in feed have no limits on the 
duration of use.87 Even for those antibiotics for which there are specified durations, it would be within a 
veterinarian’s prerogative to authorize several back-to-back, short duration uses for disease prevention, even 
in the absence of a particular disease diagnosis. This kind of usage, in terms of selection for the emergence 
and spread of resistance, would not appear to be much different than continuous in-feed use of low-dose 
antibiotics for growth promotion.   
The Current U.S. Approach
The U.S. is among the 193 U.N. member states that declared in September 2016 their commitment to work 
together to address the root causes of the resistance crisis across human health, animal health and agriculture 
settings.88 Members re-committed to preparing national action plans modeled after the WHO Global Action 
Plan on Antimicrobial Resistance.   
CARB, completed in March 2015, sets specific, numeric goals for reducing inappropriate antibiotic use 
in hospitals and outpatient settings by 20% and 50%, respectively (see Table 1). Examples of inappropriate 
antibiotic use include antibiotics that are wrongly prescribed for viral infections, such as colds; antibiotics 
incorrectly given for an infection for which they lack antibacterial activity; and antibiotics prescribed for a 
longer period of time than is necessary. CARB also sets specific goals for better surveillance and monitoring 
of antibiotic resistance linked to drug use in human medicine. 
Combating Antibiotic Resistance:  
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Table 1. Comparing CARB’s Approach: Reducing Antibiotic Use in People vs. Food-
Producing Animals 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibiotics in Human Medicine Antibiotics in Food Animal Production
 
Starting point: 
 
Accounts for 30% of all medically 
important antibiotics sold 
 
Preventive antibiotic normally not  
used in the general population 
 
Preventive use in limited  
circumstances, for example in  
patients with pre-existing conditions: 
 
Patients before surgery can get  
antibiotics to prevent surgical site 
infections 
 
Dental patients with abnormal heart 
valves get antibiotics prior to dental 
procedures
 
Starting point: 
 
Accounts for 70% of all medically 
important antibiotics sold 
 
Medically important antibiotics 
routinely fed to flocks or herds for 
disease prevention, absent a diagnosis of 
disease 
 
Until recently, antibiotics were allowed 
to be used to speed up animal growth, 
i.e. “growth promotion”
CARB Includes: CARB Includes:
Firm numerical targets for reduction  
of inappropriate use in different  
settings: 
 
     20% in inpatient settings  
 
     50% in outpatient settings
No targets for reduction 
 
Relies on FDA’s elimination of growth 
promotion uses, estimated at 10-15% of 
use (at most): 
 
Concern: While growth promotion use 
has been eliminated, similar or identical 
use can continue to “prevent” diseases in 
animals that are not sick, as a substitute 
for improved management practices
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CARB does not set meaningful goals related to 
antibiotics used in food animal production. First, it 
sets no numeric goals for reducing antibiotic use 
overall, which is worrisome given the high volume 
of use in the livestock sector. Second, current 
national efforts to monitor antibiotic use on farms 
are mostly non-existent and the integration of 
antibiotic use data with surveillance of the spread 
of antibiotic resistance is inadequate. Under CARB, 
goals for addressing these shortcomings are sparse 
and vague.  
Brief History of FDA Efforts
More than four decades ago, the FDA made a 
scientific finding that certain antibiotics given 
to food-producing animals at “sub-therapeutic” 
levels (e.g. for growth promotion, feed efficiency, 
and disease prevention) posed a threat to human 
health because of antibiotic resistance concerns.89 
FDA subsequently proposed in 1977 to withdraw 
approvals for such uses of penicillins and 
tetracyclines, but it did not follow through.90  While 
CARB largely defers to FDA to address antibiotic 
use in food animal production, FDA’s efforts to 
date have targeted only a small portion of total 
antibiotic use.  As described below, the agency has 
set no targets for reduction of use, and has included 
few safeguards to monitor and adjust for changes in 
usage levels.  Moreover, a recent assessment by the 
independent Government Accountability Office 
(GAO), published in March 2017, concludes that 
without clearer objectives, still-inadequate data 
collection and no metrics in place for measuring 
effectiveness, the agency cannot know whether the 
steps it has taken have improved the management of 
antibiotics used in food animal production.91  
Phase-out of growth promotion claims, but 
approval for disease prevention use continues 
In its 2013 Guidance for Industry #21392, the 
FDA urged drug makers to voluntarily remove 
growth promotion language or “claims” from their 
medically important antibiotic products sold for 
use in animal feed or drinking water. Companies 
removed those claims and FDA subsequently 
codified the changes in January 2017. However, the 
elimination of antibiotics for growth promotion 
alone is not likely to significantly reduce antibiotic 
use in food animal production;  both the animal 
pharmaceutical industry and the FDA estimate 
that growth promotion use accounts for no more 
than 10% to 15% of all antibiotic sold for use 
in animals.93 Furthermore, many of the same 
antibiotics sold for use as growth promoters are 
also FDA-approved and labeled for the purpose of 
disease prevention, including at dosage levels and 
durations that are similar to or the same as those 
previously approved for growth promotion.94,95 
This means that mass administration of medically 
important antibiotics for long periods of time may 
continue.  
Veterinary oversight without other safeguards
Under Guidance #213, the sale of medically 
important antibiotics for use in feed or drinking 
water for disease prevention, control or treatment 
can continue, but the FDA recently put such uses 
under the oversight of a veterinarian. Purchasing 
the antibiotics requires a feed directive (called a 
VFD) or a veterinary prescription.  
However, there are no policies or tools in place to 
monitor and track how well veterinarians oversee 
or prescribe the use of these antibiotics in livestock 
production. For instance, there are no systems to 
compare antibiotic prescription patterns among 
veterinarians, or even to identify high prescribers as 
the first step in helping them modify their use of 
antibiotics. In addition, there are no systems or 
means for discouraging farms from shopping around 
for a veterinarian who might be more willing than 
his or her peers to prescribe antibiotics. In these 
two respects, the U.S. suffers by comparison to 
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Denmark and the Netherlands, where such systems 
are in place (described on page X). Finally, U.S. 
veterinarians are frequently employed by and write 
prescriptions on behalf of large meat production 
companies.  A 2011 GAO report supports the 
concern that conflicts of interest could interfere 
with the determination of whether antibiotics for 
these food-producing animals are in fact necessary.96 
 
Recommendations to Decrease 
Livestock Use of Medically Important 
Antibiotics 
 
To successfully combat the crisis of antibiotic 
resistance, the U.S. must meaningfully reduce use of 
antibiotics in food animal production, as well as in 
human medicine. The recommendations below 
draw on science and successful efforts to reduce 
antibiotic use in human medicine in the U.S. and in 
livestock production in Europe.   
 
We acknowledge there may be significant cultural 
differences between the U.S. and countries such as 
Denmark and the Netherlands that may affect how 
some of our recommendations would be 
implemented. However, many of these 
recommendations already are being implemented in 
the U.S. within human medicine (See Table 1), by 
some U.S. food producers, and by some individual 
states. Our broad recommendations also can be 
adapted to different sectors and institutions (e.g. 
hospital food service, restaurants, etc.) in ways that 
the appendices to this report explain further. 
 
Recommendation No. 1:  Set targets for reducing 
antibiotic use 
 
Antibiotic use reduction targets are a well-
established policy tool for achieving change. For 
example, the Dutch livestock sector and 
government were able to reduce sales and use of 
antibiotics in food animal production by more than 
60% in part by setting reduction targets. (See 
Appendix E.) Analyses of their efforts have pointed 
to target-setting as a key component of success in 
both Denmark and the Netherlands.97  
 
CARB also found value in setting reduction targets 
in both inpatient and outpatient settings. We 
recommend that similar reduction targets be 
established in food animal production. Target setting 
should be accompanied by strong data collection 
programs and benchmarking to ensure that 
reductions are achieved and high users are identified 
for improvements. 
 
While reduction targets ideally would be set at the 
federal level, state governments and even private 
actors can make significant contributions by setting 
their own targets.  
 
Recommendation No. 2:  Phase out routine or 
programmed antibiotic use  
 
We recommend a policy to phase out the routine or 
programmed administration of medically important 
antibiotics over long periods of time to flocks or 
herds of animals. (‘Programmed’ use of antibiotics 
refers to when animal management protocols or 
guidelines have been written so that antibiotics are 
regularly administered at a particular phase of 
production, irrespective of any particular disease 
diagnosis.) This can be combined with target 
setting, as in the Netherlands, or pursued 
independently as in Denmark. Both countries have 
phased out antibiotic growth promoters and other 
uses of antibiotics in the absence of disease, and 
have achieved reductions of 45% to 60%. The 
American Academy of Pediatrics98 and the 
European Medicines Agency/European Food Safety 
Authority99 also recommend only using antibiotics 
to control or treat disease. The U.S. should follow 
this lead.  
 
Absent federal action, states also can take steps to 
phase out routine or programmed antibiotic use in 
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food-producing animals within their borders. 
California has already done so by banning the use 
of antibiotics for disease prevention “in a regular 
pattern of use,” starting in 2018.100  
 
The private and public sectors also can take action. 
Major food companies that have instituted policies 
to phase out the routine use of antibiotics for all or 
some of the meat they source include Chipotle, 
Chick-fil-A, Panera, Subway, KFC and McDonalds. 
Public schools and hospitals also are increasingly 
purchasing meat and poultry where antibiotics are 
either disallowed or allowed only for treating or 
controlling disease, but not allowed for  
routine use for disease prevention. Even individuals 
and families can set goals for themselves by 
purchasing meat that reflects responsible antibiotic 
use practices.  
 
Both private and public sector actors should also 
take action to support antibiotic stewardship 
programs that emphasize better management 
practices to prevent disease and reduce or avoid the 
need for antibiotics in the first place.  
 
Recommendation No. 3:  Reduce the need for 
antibiotics by adopting non-antibiotic best 
practices, and by innovating new technologies, to 
maintain animal health and prevent disease.  
 
Even where antibiotics are being used to treat 
disease, there often are opportunities to reduce or 
avoid that use altogether by changing animal 
management practices or investing in new 
technologies, such as vaccines, to keep animals from 
getting sick in the first place. Non-antibiotic disease 
prevention is confirmed in both science and 
practice. For example, in February 2017, the 
European Medicines Agency along with the 
European Food Safety Authority, published an 
extensive scientific opinion detailing evidence-
based management practices in food animal 
production that reduce or avoid the need for 
antibiotics.101 Additionally, Kansas State 
University102, the American College of Veterinary 
Internal Medicine103, and the National Pork 
Board104 also emphasize that responsible antibiotic 
use involves reducing the need for antibiotics, such 
as non-antibiotic measures to improve animal health 
and prevent disease.  
 
In the private sector, McDonald’s has incorporated 
this principle into its 2015 Vision for Antimicrobial 
Stewardship for Food Animals which articulates 
four goals for its global meat supply chains, 
including: “Utilize animal production practices that 
reduce, and where possible eliminate, the need for 
antimicrobial therapies and adopt existing best 
practices and/or new practices that would result in 
subsequent reductions of antimicrobial use.”105  
 
Recommendation No. 4:  Eliminate antibiotic use 
where efficacy can no longer be demonstrated.   
 
Antibiotic products that are FDA-approved for use 
in livestock or poultry production must have been 
shown to be efficacious at the time of approval. 
Those approvals, however, may have occurred 
decades ago and may no longer be accurate.  Newer 
data may be available showing reduced efficacy as a 
result of significant changes in animal agriculture 
since the drugs were first approved. Some drugs 
were first approved over 50 years ago and have 
never been re-evaluated by the FDA.  
 
Recommendation No. 5:  Prioritize the use of 
antibiotics in veterinary practice that the WHO 
does not categorize as “critically important” for 
human medicine.  
 
Among all antibiotics considered medically 
important by the World Health Organization 
(WHO)106 are some categorized as “critically 
important” for human medicine. On this list are 
several classes of antibiotics that are FDA-approved 
for use in food-producing animals in the U.S., 
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including 3rd-generation cephalosporins, fluor-
oquinolones, macrolides, aminoglycosides, penicillins 
and polymyxins.107,108 With respect to use of these 
critically important antibiotics, we recommend 
policies ensuring that in veterinary practice: 
 
A. Antibiotics in the “critically important” category 
are used only to treat animals sick with a specific 
bacterial disease. Use of the subset of  ‘highest 
priority’ critically important antibiotics (also defined 
by the WHO)109 should require testing that confirms 
the bacterium involved is not susceptible to other 
antibiotics. 
 
B. Critically important antibiotics that are not 
currently FDA-approved for food animal use in the 
U.S., such as carbapenems, should never be 
approved;  
 
The Netherlands, as described in a recent European 
Commission audit, provides one example of a policy 
framework that prioritizes the use in animals of 
antibiotics considered to be of lower importance for 
human medicine.110 All antibiotics used in farming 
there are available only under a veterinarian’s 
prescription. Since 2012, a work group of the Royal 
Netherlands Veterinary Association (KNMvD) has 
had a system for classifying these antibiotics and 
how they are to be used in order to reduce the 
selection for antibiotic resistance. First-tier or first 
choice antibiotics can be given empirically under an 
existing farm treatment plan and protocol, after a 
problem has been diagnosed. Second-choice 
antibiotics are only used after a veterinarian’s clinical 
exam and testing has substantiated the need for 
them. Third-choice antibiotics are the most 
restricted, because they are considered the highest 
priority for human medicine, such as 
fluoroquinolones and 3rd generation cephalosporins; 
they are to be used in individual animals only after 
veterinary testing substantiates that there are no 
first- or second-tier alternatives.  
 
Similar policies in the U.S. to prioritize the use in 
animals of non-critically important drugs would be 
meaningful, but only if combined with the phase-
out of medically important antibiotics used 
routinely in the absence of a disease diagnosis (such 
as for disease prevention), per Recommendation 
No. 2.  
 
In addition to or absent U.S. federal action, state and 
local governments could incorporate these 
restrictions on the use of critically important 
antibiotics in food-producing animals in legislation 
or purchasing criteria. Private purchasers of meat 
and/or poultry products likewise could build this 
recommendation into their supply chain standards 
or policies. 
 
Recommendation No. 6:  Bolster veterinary 
oversight of antibiotic use with other        
safeguards. 
 
In Denmark and the Netherlands, stricter veterinary 
oversight was instituted and combined with other 
safeguards to counter the likely increase in 
prescription use of antibiotics following restrictions 
placed on growth promotion and disease prevention 
uses. Those safeguards include: restrictions placed on 
certain kinds of uses, restrictions on veterinarian 
profits from the sales of antibiotics, and new 
accountability measures such as benchmarks for 
antibiotic use by farms and veterinarians (e.g. 
“Yellow card” or comparable programs to identify 
high users of antibiotics and help them to improve 
their performance). (See Appendix E).  
 
Some safeguards along these lines are already in 
place in U.S. human medicine. The American 
Medical Association, for example, cautions U.S. 
physicians that profiting from the sale of health-
related products, including antibiotics, from their 
own offices creates a financial conflict of interest, is 
unethical and therefore not allowed.111 Also, under 
the Physician Payments Sunshine Act of the 
19
Affordable Care Act, manufacturers of pharmaceuticals as well as medical devices must divulge financial 
payments to physicians and hospitals, and these become a matter of public record.112 
 
The U.S. government can and should play a key role to ensure stronger veterinary oversight of antibiotic use 
in food animal production. State governments also can implement strong data and benchmarking policies 
regarding antibiotic use in food-producing animals within their borders. Similarly, major purchasers of meat 
and poultry can track the use of medically important antibiotics in their supply chains and benchmark 
performance to drive reductions. 
 
 
Table 2. Comparing U.S. Veterinary Oversight Provisions to Denmark and the Netherlands
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
United States
 
Denmark (DK) and the  
Netherlands (NL)
 
 
Restrictions
 
Growth promotion uses ended; 
Routine disease prevention allowed
 
Both DK and NL have banned 
growth promotion and disease 
prevention uses
 
 
 
 
 
 
Veterinarian 
oversight,  
accountability 
 
 
Vet oversight mostly required,  
except for select over-the- 
counter injectable antibiotics 
 
No limits on profiting from sales 
 
No tracking of how much  
individual vets prescribe antibiotics 
 
No farm registration of vets  
required
 
 
Vet oversight of antibiotics  
required in DK, NL 
 
DK - Farms required to have a 
contracted veterinarian at all times 
 
NL - Requires farms to have a 
one-to-one relationship with a 
veterinarian. 
 
DK  - Vet profiting from direct sales 
capped at 10% (profits hit 30%  
before cap)
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B.  Monitoring Antibiotic Use to Reduce Antibiotic 
Resistance
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The collection of antibiotic use data is critical for managing and minimizing antibiotic 
resistance, as recognized by the GAO113, the World Organization for Animal Health 
(OIE)114 and the WHO.115 
 
Better data are essential to fully understand how and why antibiotics are used 
in food animal production and how that use varies by species, region and over 
time. Understanding patterns of use and trends in antibiotic resistance can help 
policymakers direct resources so it has the greatest possible impact. It also will allow 
for the success (or failure) of specific interventions to be better monitored so that 
adjustments can be made. Similarly, food animal producers need better data to develop 
improved antibiotic use strategies, including setting targets for and tracking progress 
toward reducing unnecessary use.  
 
The usefulness of antibiotic use data is influenced by the choice of metric in reporting 
that data. The choice of a particular metric can, in turn, reflect the setting in which 
antibiotic use occurs as well as the robustness of the underlying data.  Also guiding the 
choice of metric is the purpose for which those data are being utilized (i.e. tracking 
trends in antibiotic use; comparing antibiotic use between countries or between 
animal species; or for determining any association between particular antibiotic  
uses and resistance).116
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The Current U.S. Approach to Data 
Collection 
 
Antibiotics sold for use in food animal production 
far outstrip those sold for use in human medicine. 
To successfully address the antibiotic resistance 
crisis, reliable data on how and why antibiotics 
are used in food animal production is a critical 
element. Without such information, national 
efforts to confront the crisis of antibiotic resistance 
are likely to fall short.
 
In the U.S., data related to food animal production 
are collected along three data streams. Since 
2009, drug companies have been required to 
supply the FDA with information on antibiotics 
sales for use in food-producing animals, which 
the agency publicly issues as an annual report. It 
includes information on the intended route of 
administration (e.g. via animal feed, drinking water 
or injection), and the antibiotics’ dispensing status 
(i.e. over-the-counter, prescription, or veterinary 
feed directive). Starting in 2017, the FDA also will 
require drug companies to estimate antibiotic sales 
broken down by major food-producing species 
(cattle, swine, chickens and turkeys). The agency 
cautions that these estimates may be incomplete 
and not match actual antibiotic use at the farm 
level.  
 
The U.S. Department of Agriculture (USDA) 
collects the only publicly available data on actual 
farm-level use of antibiotics. Data is collected 
through voluntary farm surveys on animal health 
and management, conducted since 1983 by the 
agency’s National Animal Health Monitoring 
System (NAHMS). Information for each livestock 
sector is collected only once per five- to seven-
years; the questions asked can vary from one 
survey to the next. Both factors make year-to-year 
comparisons basically impossible, and trends more 
difficult to establish, while also eroding the data’s 
usefulness in assessing the impacts on farm practice 
of any specific policy changes related to antibiotic 
use. Finally, the surveys are voluntary, and therefore 
not comprehensive by definition. Voluntary surveys 
also may be unintentionally biased, since farms 
that choose to participate may not accurately 
reflect the industry as a whole.  
 
In 2011, the U.S. Government Accountability 
Office summarized the program’s shortcomings as 
follows:   
 
“....NAHMS is limited by long lag times 
(approximately six years) between surveys of the 
same species, changes in methodology and survey 
populations between studies, reliance on voluntary 
participation by food animal producers, and 
collection of qualitative, rather than quantitative 
information on antibiotic use.”117 
 
Further illustrating the shortcomings, the chicken 
and turkey surveys do not ask about antibiotics 
use (See Table 3). Only beef, dairy and swine 
producers are asked about what antibiotics have 
been used on their farms in the last six months, 
the route of administration, the age of the 
animals (e.g. nursery or finisher pigs), and general 
reason for use (e.g. growth promotion, disease 
prevention, disease control, disease treatment). 
The USDA recently announced that antibiotic-
specific surveys for swine farms and beef feedlots 
are being conducted in 2017.118 While they may 
provide some additional data, these surveys will 
carry the same aforementioned limitations as 
other NAHMS surveys119, while also combining 
reporting on antibiotics used for treatment, 
control and prevention purposes so as to make it 
impossible to distinguish between those uses.120 
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Table 3: Overview of major poultry, livestock studies conducted by NAHMS, 2006-2016
Year studies were 
conducted, 2006 - 16
Information on  
antibiotic use
Information on  
antibiotic resistance
Chicken 2007, 2010
Turkey 2007, 2010
Swine 2006, 2012
Beef (cow-calf) 2007
Beef (feedlot) 2011
Dairy 2007, 2014
The USDA collects some limited, additional antibiotic use data from farms as part of annual surveys of farm 
finances in its Agricultural Resource Management Survey (ARMS) program, jointly conducted by the 
National Agricultural Statistics Service (NASS) with the Economic Research Service.121 NASS also collects 
important information on the number of animals raised in the U.S. that are needed to interpret antibiotic 
use data.  The ARMS surveys included questions about antibiotic use in swine farms in 2004, 2009, and 2015 
and on broiler farms in 2006 and 2011.  These surveys, however, contain much less detail on antibiotics than 
the aforementioned NAHMS surveys; they provide only general information on whether or not a farm used 
antibiotics for a specific purpose (e.g. growth promotion, disease prevention, or treatment), and provide no 
information on specific antibiotics used.  These data also carry the additional limitations of the data collected 
under NAHMS as they are sporadic and voluntary.
In short, antibiotic use information available in the U.S. is simply inadequate to fully address the antibiotic 
resistance threat to human health. Without more detailed and comprehensive information, we cannot have 
an accurate picture of how antibiotics are sold, distributed, and used in food animal production.  The absence 
of this is likely to hamper policymakers and healthcare leaders trying to tackle antibiotic resistance because 
changes and trends cannot be accurately tracked, and resources may not be focused where they are most 
needed. 
 
Examples of Comprehensive Data Collection Systems  
 
Successful models do exist for collecting and analyzing how and why antibiotics are used in food animal 
production (See Box C). In each model, the government, livestock industry and veterinarians all play 
important, albeit somewhat different, roles.  
 
In Denmark, a national database called VETSTAT serves as a repository for data on drug usage at the herd 
level. It is collected from three sources allowed to dispense antibiotics: veterinary pharmacies, veterinarians 
and feed mills.122  VETSTAT, funded by the Danish Ministry of Food, Agriculture and Fisheries, is then used 
as a resource to set national goals and thresholds, as well as to benchmark antibiotic use at the individual farm 
level. In the Netherlands, an expert panel of the independent Netherlands Veterinary Medicines Authority 
(known as SDa), reviews the data from 40,000 livestock farms, sets benchmarks on antibiotic use and issues 
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an annual report on its findings.  The data come from the large animal production sectors themselves, which 
have recently instituted centralized registration systems that monitor antibiotic use on all farms, and from 
FIDIN, the federation of the Dutch veterinary pharmaceutical industry, which reports on annual sales of 
antibiotics. 
These different models for data collection Illustrate different approaches to ensuring farm anonymity. In the 
Netherlands, the industry associations maintain and track the data and provide anonymized information on 
usage to the independent SDa. In Denmark, the government can access farm-specific data more freely, but 
the public must make a special request to access it.  
Recommendations for Improving U.S. Data Collection
The following recommendations encompass a discussion of the essential data that should be collected (See 
Box D), potential sources of data, as well as options for metrics that synthesize the available data and allow 
for comparisons of antibiotic use.  
Recommendation No. 7:  Develop a system for collecting detailed, comprehensive data on actual 
antibiotic use, and collect essential data 
We call on federal agencies, working with states and producer groups, to develop a system for collecting 
detailed, reliable data on the use (not just sales) of antibiotics at the farm level, or at the level of the 
veterinarians overseeing their use. 
The FDA acknowledges that gathering information on the way medically important antibiotics are 
used is essential to measuring whether its current strategy is working to ensure that antibiotics are used 
appropriately in food-producing animals. However, the agency has no system in place to collect ongoing 
and comprehensive use data, nor does it have any stated intention to build such a system. Each of the 
current separate programs collecting data pertaining to U.S. antibiotic sales or use – FDA’s collection of sales 
data, USDA’s NAHMS surveys, feed mill records and existing state databases – should be molded into a 
unified system modeled on the experience in Denmark and the Netherlands. 
Development of unified data collection systems in Denmark and the Netherland has been critical to their 
success in reducing antibiotic use (over baseline levels) by 47% and 64%, respectively. To ensure success, 
or even to measure progress of CARB, the U.S. must also have a good data collection system. That system 
should be mandatory, not voluntary, and should be comprehensive enough to encompass certain essential 
data. 
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The limited data on antibiotic use in U.S. animal agriculture stands in stark contrast to Denmark and the 
Netherlands. Both countries have robust, profitable meat and poultry industries where they raise animals 
in intensive, industrial-style operations not unlike those in the U.S. Both have adopted policy and practice 
changes that have helped to significantly curtail unnecessary antibiotic use in food animal production. In 
each country, the changes include improved monitoring of antibiotics sold and used in food-producing 
animals as well as surveillance to identify patterns of resistance in people, retail meat and in food-producing 
animals. Antibiotic sales, use and surveillance information for each country also are integrated into a 
single annual report.123,124 No such integrated report is prepared in the U.S., as is discussed later. The 
enhanced systems for collecting and integrating data in the two countries have informed additional policy 
interventions over time by identifying areas in need of improvement. They also have made it possible to 
benchmark how well veterinarians and/or farms use antibiotics relative to their peers. These systems have 
been crucial in enabling the countries to reach their antibiotic use goals and reduction targets as well as 
keep antibiotic resistance in animal populations at low levels. Data, in other words, are central to driving 
improvements in antibiotic use.  
 
Denmark – Responding to public concern about levels of antibiotic use in food-producing animals, and 
possible impacts on human health, Denmark began taking a series of important steps in 1995, including 
improving data collection.  It established DANMAP, the Danish Integrated Antimicrobial Resistance 
Monitoring and Research Program, which: 1) monitors antibiotic use in food-producing animals and people; 
2) monitors occurrence of antibiotic resistance in bacteria from food-producing animals, food of animal 
origin and people; 3) identifies trends and puts together information on associations between antibiotic 
use and resistance; and 4) identifies routes of transmission and areas for further research.125 Individual farm 
level data are collected from veterinarians, pharmacies and feed mills and reported to a centralized system 
(VETSTAT). VETSTAT information can be accessed by farmers or veterinarians, allowing them to compare 
their level of use to a national average.  
 
 
 
 
 
 
The Netherlands – In 2009, public concern in the Netherlands led the four main livestock sectors (veal, 
cattle, pigs and poultry), along with other stakeholders, to establish a task force on antibiotic resistance. 
Later that year, industry and government together set a goal for reducing antibiotic use by 50% within five 
years. The independent SDa was formed in 2010, and serves as a repository for sales data collected from the 
pharmaceutical industry, and for prescription data collected by the livestock industry and then provided in 
an anonymized form to the SDa. SDa is a public–private partnership between government, the Royal Dutch 
Veterinary Association and the livestock industries.
Box C:  Comparing U.S. Data Collection Efforts to Denmark and the Netherlands
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Box D: What Data Should Be Collected?
Certain minimum data are essential to capture a meaningful picture of how and why 
antibiotics are being used in animal agriculture. It is critical to know:  
 
  Antibiotic administered; 
  Species (pigs, turkeys, chickens, beef and dairy cattle) on which the  
  drug was used;  
  Purpose of use and/or indication (disease treatment, disease   
  prevention/control, type of infection such respiratory illness, etc.); 
  Route of administration (feed, water, oral, injection, intramammary,  
  topical, other); 
  Volume of antibiotic active ingredient;  
  Duration of use; and 
  Number of animals receiving the antibiotic. 
 
Ideally, the following additional information also would be collected to provide a more 
complete understanding of use and resistance patterns:  
 Dose of the antibiotic administered; 
 Production class (dairy cattle vs. beef cattle, etc.); 
 Age of animal (sows vs. piglet; if interested in daily dose);  
 Region; 
 Farm identification (potentially anonymous); 
  Veterinarian identification (potentially anonymous) 
 
Data Sources 
 
Data could be collected from several different sources, as described in the Danish and 
Dutch examples. At the federal level, for example, FDA could collect information 
from feed mills on antibiotics mixed into animal feed and then sold for use on farms. 
Currently, it does not do this and feed mills are only required to maintain records and 
make them available to the FDA, if requested. Similarly, the USDA could implement 
a yearly survey representative of the food animal production sector to collect 
information on how and why antibiotics are used. 
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In absolute terms, especially relative to the 
enormous potential economic losses if effective 
antibiotics are no longer available in the future, the 
near-term costs of building this system are unlikely 
to be large relative to the magnitude of the threat. 
For example, experts in Denmark indicate that a 
recent overhaul of VETSTAT, their comprehensive 
data collection system, is going to cost an estimated 
$3.2 million; ongoing operations will cost an 
additional $450,000 a year.  
 
States and private actors in the U.S. also could play 
significant roles in collecting and reporting data on 
antibiotic sales and use. For example, California’s 
law addressing antibiotic use in livestock includes a 
requirement to monitor antibiotic sales and usage. 
Professional livestock or veterinary associations 
could collect and report use information to 
the public, as they do in the Netherlands. Food 
marketers and buyers also can help increase 
transparency by requiring suppliers either to report 
antibiotic use to them directly, or to participate in 
government or other data collection systems. 
 
Recommendation No. 8:  Coordinate with and 
learn from other countries in developing a 
comprehensive data collection system. 
 
The most efficient means to develop a U.S. 
database on antibiotic use is to build on appropriate 
models currently in place in Europe, modified to 
accommodate how antibiotics are regulated and 
distributed at the state and federal levels. The U.S. 
can take advantage of the fact that several European 
countries have already spent a decade or more 
building comprehensive data collection systems, and 
integrating them with national surveillance of trends 
in antibiotic resistance. Also, in signing onto the UN 
declaration, the U.S. signaled its commitment, to 
cooperate to combat antibiotic resistance and the 
global public health threat it represents. 
 
 
Recommendation No. 9:  Adopt a metric for 
reporting data on antibiotic sales or use that 
better allows trends to be identified, explained, 
and compared. 
 
Data on antibiotic sales or use are most useful in 
a policy setting when they are expressed using a 
metric that facilitates comparisons, such as across 
time, animal species, or countries. Appendix A 
describes different metrics in use today. Until a 
better system is put into place to collect more data 
(detailed in Box D) the U.S. should employ a metric 
for reporting on antibiotic use that can inform its 
efforts to eliminate unnecessary and inappropriate 
use, as well as to allow for comparisons with other 
countries. In the near-term, the U.S. can and should 
employ the mg/PCU metric. This measures the 
amount of antibiotics sold per amount of livestock 
raised. The longer-term goal should be to transition 
to use of an animal defined daily dose metric, a drug 
and animal species-specific measure that requires the 
collection of additional data. 
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C. Enhancing Surveillance and Data  
Integration to Inform Antibiotic Use Policy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The previous section described three streams of data currently being collected in 
the U.S. concerning livestock use of antibiotics: FDA’s collection of sales data from 
the animal drug makers; USDA’s periodic voluntary surveys of farms; and the NASS 
collection of data on numbers of animals raised. The National Antimicrobial Resistance 
Monitoring System (NARMS) represents a fourth stream of data collection. NARMS 
is a surveillance program that monitors for antibiotic resistance among bacteria 
isolated from people, retail meat and food-producing animals at the slaughterhouse, 
and is discussed in greater detail below. Individually, each data stream provides some 
meaningful information, but the usefulness of the data is shortchanged by a failure 
to combine the different data streams into an integrated analysis to provide a more 
comprehensive picture of antibiotic use in food-producing animals. What follows 
is a more detailed discussion of the NARMS surveillance program, followed by 
recommendations for better integration of the various streams of data collected by  
the federal government. 
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National Antimicrobial Resistance Monitoring System (NARMS) 
 
Since 2003, the NARMS program has been providing surveillance on a national basis for antibiotic 
resistance in enteric (‘gut’) bacteria. NARMS surveillance work is conducted by three federal agencies 
(CDC, FDA and USDA) and studies bacteria collected from people, the retail meat supply, and food-
producing animals, respectively.  
 
In short, public health laboratories submit bacteria from cases of human infection to NARMS, where, led by 
the CDC, they are tested for resistance to antibiotics. FDA receives bacteria from samples of retail chicken, 
ground turkey, ground beef and pork chops collected each month by laboratories in 14 states. FDA scientists 
further characterize the bacteria and test them for resistance to antibiotics.126 USDA scientists conduct 
similar tests on bacteria obtained from food-producing animals at federally inspected slaughterhouses and 
processing plants. 
 
NARMS is valuable for monitoring trends in antibiotic resistance in people, food and in food-producing 
animals. NARMS would be stronger, however, if it reflected emerging research techniques and the latest 
science. Its failure to do so means that the NARMS program is falling behind in meeting its stated goal to 
“protect public health by providing information about emerging bacterial resistance”.127 Below are three 
specific shortcomings of the program, reflecting an outdated approach: 
 
No consistent monitoring of indicator bacterial species. NARMS currently focuses too narrowly on bacteria 
that are conventionally considered to be foodborne causes of infection, such as Salmonella or Campylobacter. 
Other bacteria, such as Escherichia coli and Enterococcus spp. also are found in the food supply, can cause disease 
and are considered to be “indicator” species that can signal existence of a broader reservoir of antibiotic 
resistance. Only four of the 14 state laboratories participating in the NARMS retail meat program collect 
samples of these so-called indicator bacteria for later testing by FDA for antibiotic resistance. In addition, 
there is a lack of uniformity between agencies in terms of which indicator species they monitor (see Table 
4). Both problems create a significant challenge for NARMS to track antibiotic resistance in a coordinated 
and complementary manner along the entire food supply chain.  
 
Table 4: Overview of NARMS Testing According to Bacterial Species
Bacterium Tested by CDC Tested by FDA Tested by USDA
Salmonella
Campylobacter spp.
Enterococci spp.
E. coli
E. coli O157
Shigella
Vibrio spp.
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Does not apply genetic sequencing to indicator 
bacteria and pathogens other than Salmonella.  
Federal efforts to begin sequencing the entire 
genome of certain bacteria collected under 
NARMS have focused almost entirely on 
Salmonella.128 However, recent studies show that 
other indicator bacteria, such as E. coli, are the most 
common bacteria in livestock environments found 
to be carrying genes that easily spread resistance 
to antibiotics of last resort (such as colistin or 
carbapenems) to other bacteria.129 Clinicians rely 
upon these last resort medicines to treat life-
threatening infections when other drugs have failed, 
or are likely to fail.  
 
There are two key reasons to sequence the genes 
of bacteria such as E. coli or Enterococcus spp. and not 
just Salmonella. First, resistance genes found in either 
one are important because that resistance could 
subsequently be shared between the two groups of 
bacteria, in any environment. Second, these bacteria 
are more commonly found in livestock and other 
environments so resistance trends are more easily 
monitored in these bacteria. For both reasons, 
sequencing only the genomes of Salmonella bacteria 
would be likely to contribute to incomplete 
identification of and surveillance for antibiotic 
resistance genes in livestock environments.  
 
Metagenomics is a powerful technique, first named 
in 1998130, that looks at the DNA recovered from 
all bacteria in a particular environmental sample. 
Because the FDA and USDA already have the 
ability to sequence genes of individual bacteria,131,132 
that capability likely could be easily adapted to 
detect resistance from all of the bacteria isolated 
from a particular animal or meat sample. We can 
and should expect the NARMS program as well 
to use metagenomics to comprehensively detect 
emerging resistance in all bacteria, and not just in 
Salmonella, Campylobacter, E. coli and Enterococcus spp. 
 
 
Fails to test for resistance to all antibiotics relevant 
to human medicine. NARMS’ limitation is that the 
panel of antibiotics to which bacteria are tested 
for resistance will vary according to the species of 
bacteria being tested, and that these test panels also 
are too limited in scope to fully assess reservoirs of 
resistance. NARMS antibiotic susceptibility testing 
focuses only on classes of antibiotics used in food 
animal production and/or the classes commonly 
used to treat human infections. This overlooks 
other antibiotics of importance to human medicine. 
Colistin is an example of an antibiotic that has 
only recently become more common in human 
medicine, as resistance to other, less toxic agents 
forced practitioners to return to using it. And now 
colistin-resistant bacteria, likely enriched by overuse 
of the drug in pig production (outside of the U.S.), 
are spreading around the world.133,134 
 
Roadmap Recommendations for 
Enhancing Surveillance and Data 
Integration 
 
In light of the shortcomings of U.S. surveillance 
of antibiotic resistance, we propose the following 
recommendations:  
 
Recommendation No. 10:  Integrate available 
data into a single, comprehensive report
 
CDC, FDA, and USDA, should publish a joint, 
integrated report that summarizes the following: 
antibiotic resistance data (NARMS, NAHMS), 
antibiotic sales data (ADUFA, IMS Health135), 
antibiotic use data (NAHMS, CDC136), and 
livestock production statistics (USDA/NASS). The 
report should draw the best connections between 
the data possible. In the absence of a national report, 
state policymakers can publish a regional report by 
requesting state level resistance data from NARMS 
and livestock production statistics coupled with 
new surveillance of state-level antibiotic use, such as 
will soon be collected in California. 
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The annual DANMAP and NETHMAP/MARAN 
reports are examples of integrated, comprehensive 
reports that combine data on antibiotic use/
sales and antibiotic resistance.137 Both serve as 
foundational documents for effective policymaking 
in both countries. Reports from both countries 
also contain additional information such as yearly 
livestock/production data (such as that available 
from USDA138 in the U.S.), and provide a basis 
for a rough metric that facilitates international 
comparison of milligrams of antibiotics used or  
sold per kilogram of animal weight after slaughter.  
 
Recommendation No. 11:  Improve surveillance 
to detect new and emerging resistance threats 
 
The public health goal of any surveillance system 
should be to detect problems earlier rather than 
later. Early detection is more likely to result in an 
intervention that succeeds in addressing problems 
that arise. Later detection, on the other hand, may 
result in being able to recognize that a problem 
exists, but not being able to do anything about it. 
In order to improve and/or expand upon the scope 
of NARMS current surveillance, the government 
agencies responsible for the program should 
leverage the latest science to elucidate new and 
emerging health threats from antibiotic resistance.  
 
For example, recent scientific studies clearly 
indicate that multidrug-resistant S. aureus bacteria, 
including MRSA, are present in food-producing 
animals and on U.S. retail meats.139,140 These 
“livestock associated” antibiotic-resistant bacteria 
have been found to colonize the nasal passages of 
swine and poultry workers, and also can cause skin 
and soft tissue infections in workers, as well as other 
community members.141,142,143 In addition, certain 
strains of disease-causing E. coli bacteria (extra-
intestinal pathogenic E. coli, or ExPEC) that can 
be transmitted from food-producing animals/retail 
meat to people have been characterized by several 
studies as a probable source of human urinary tract 
infections.144,145 Some of these EXPEC bacteria 
produce an enzyme called extended-spectrum 
beta-lactamase (ESBL) which mediates resistance 
to a number of important and often-prescribed 
antibiotics, such as penicillins and cephalosporins. 
 
Finally, transmissible plasmids have been discovered 
recently on U.S. pigs146 or on pig farms147 that 
carry resistance to colistin or carbapenem, two 
antibiotics considered to be of last resort for some 
of the deadliest antibiotic resistant bacteria we face 
today. When genes that are resistant to both of these 
medicines eventually land on the same plasmid, and 
that plasmid spreads to other bacteria, it will mark 
the emergence of widespread untreatable infections. 
This discovery on U.S. pig farms lends weight to 
the conclusion that there are resistance threats in 
the food supply chain that are not being adequately 
monitored.148  Of 15 serious and urgent antibiotic-
resistant threats identified in a 2013 CDC report, at 
least eight are bacteria that have been detected both 
in U.S. food-producing animals and in retail meat 
from the U.S. or abroad.149  Three of these (MRSA, 
VRSA, and multidrug-resistant Pseudomonas 
aeruginosa) are not captured by the current 
surveillance system, and another two are only 
partially captured (CRE, ESBL Enterobacteriaceae). 
 
As a surveillance system, NARMS suffers because it 
does not consistently look for antibiotic resistance 
among newly emerging pathogens or among 
bacteria where important reservoirs of resistance are 
first thought to emerge. We therefore recommend 
the following specific expansions: 
 
11a. Expand surveillance for emerging resistance 
using next generation sequencing technology. 
Both FDA and USDA currently sequence the 
genomes of traditional foodborne pathogens tested 
through NARMS. These sequencing efforts should 
be expanded to a wider array of bacteria, including 
E. coli and Enterococcus which can be important 
reservoirs of resistance that can spread to other 
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bacteria. The agencies should set up a publicly accessible database or make use of existing databases for the 
timely release of genome sequencing data.150 
 
11b. Expand surveillance for important emerging pathogens. Emerging threats from pathogenic bacteria 
could be better characterized and assessed if NARMS were expanded to include additional surveillance for 
S. aureus and ExPEC E. coli from people, retail meat and food-producing animals, as well as testing these 
bacteria for susceptibility to antibiotics. If sufficient funding from regulatory agencies is not available, a less 
preferable alternative would be for NIH or CDC to authorize research funding for the proposed expansion 
of NARMS testing, on a pilot basis.   
 
11c. Pilot test approaches that comprehensively detect resistance in all bacteria in a sample. As noted 
above, the NARMS program can and should explore the use of metagenomics to detect emerging resistance 
in all bacteria, and not just in Salmonella, Campylobacter, E. coli and Enterococcus spp.  With metagenomics, the 
resistance information collected also is no longer limited to a few antibiotics; rather, the results from a sample 
are compared, simultaneously, to a comprehensive database collection of known resistance genes.  Again, 
expanding metagenomic analysis within NARMS could take place as a pilot, if funds couldn’t be secured 
through regular budgetary means. 
 
11d. Expand surveillance at the state level. Beyond the federal level, state veterinary laboratories have 
an important role to play in improved surveillance by publicly reporting on resistance found among food 
producing animals. For example, in 2016, the Minnesota Veterinary Diagnostic Laboratory published findings 
on resistance in Salmonella from clinical samples from 2006 to 2015 in swine and cattle.151 Public reporting 
on resistance from food animal clinical isolates at the regional level on a yearly basis would help address the 
important data gap regarding antibiotic resistance on the farm.
      Conclusion
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Conclusion 
 
Antibiotic resistance is an urgent public health threat that demands immediate action. 
Drug-resistant infections are on the rise, making antibiotics less effective and putting 
routine and common and life-saving procedures in jeopardy. Antibiotic resistance 
is changing the practice of modern medicine by compromising our ability to treat 
sick people and animals. Additionally, it is a serious threat to economic and national 
security. It is estimated that by 2050 a person will die every three seconds from a drug-
resistant infection and $100 trillion in global economic productivity will have been 
lost.152  
 
Antibiotic use and overuse in people and in food animal production are important 
drivers of antibiotic resistance. However, this report focuses specifically on antibiotic 
use in food-producing animals because 70% of medically important antibiotics sold in 
the U.S. (i.e. those identical or belonging to the same class as antibiotics used in human 
medicine) are sold for use in food-producing animals, not people. Additionally, the 
U.S. has taken significant steps in promoting better antibiotic stewardship policies and 
programs in human medicine, but falls woefully short in doing the same as it relates to 
food animal production. 
 
This Commission wants to keep the existing arsenal of antibiotics effective for as 
long as possible. We came together to craft this policy roadmap because we strongly 
believe the U.S. cannot fully respond to this public health crisis unless it does a better 
job to address the contribution to antibiotic resistance antibiotic use in food animal 
production.  
 
Our recommendations are steps that will help ensure that on-farm use of medically 
important antibiotics is monitored and reduced, and that there will be adequate 
surveillance of the development and spread of antibiotic resistant bacteria. Success, we 
believe, depends on leadership that builds on approaches that have proven successful 
elsewhere. While state and federal policymakers have important roles to play, action is 
need from all stakeholders. Health professionals and hospitals, as well as food companies 
and other major meat and poultry purchasers also have key roles to play. The appendices 
that follow outline actions for each sector. 
 
We all stand to lose when antibiotics no longer work. Steps must be taken today to help 
ensure that our existing supply of antibiotics stay as effective as possible, now and for 
future generations.
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Appendix A:  Metrics for Reporting 
on Antibiotic Use in Food-
Producing Animals 
Use of antibiotics in food-producing animals is an 
important contributor to the selection and spread 
of antibiotic resistance.  As a result, many countries 
have established national programs to monitor 
and report on the sales and/or consumption of 
antibiotics in this sector. Comparing results from 
different places or authorities is complicated. They 
may use completely different metrics. Even when 
using the same basic metric, the methodology used 
to calculate it may differ. Two countries may differ 
in the dosages they authorize for a certain antibiotic, 
or in the correction factor they employ for long-
acting antibiotic products.1 This appendix describes 
different metrics that the U.S. might employ in 
reporting its data on antibiotic sales and use, as well 
as examples of how different countries calculate 
those metrics.  
What Metrics Should Be Used? 
In the near-term, the U.S. has data sufficient to 
report on antibiotics sales/use using the metric of 
milligrams/population corrected unit (mg/PCU), 
although it does not currently do so. The mg/PCU 
metric compares the amount of antibiotics used, or 
sold for use, in food production to the total weight 
of animals being produced. The denominator, the 
population correction unit (PCU), is a calculated 
estimate of animal weight; it is a surrogate for the 
animal population at risk, one that normalizes 
antibiotic sales by animal population in individual 
countries.  
In essence, the PCU for each animal category is 
calculated by multiplying numbers of slaughtered 
animals (cattle, pigs, lambs, poultry and turkeys) and 
other livestock animals (dairy cows, sheep, sows and 
horses) by the theoretical weight at the time  
most likely for treatment. Adjustments are made for 
the numbers of animals exported or imported for 
fattening or for slaughter (cattle, pigs and poultry) 
multiplied by a standardized weight.2 
The independent European Surveillance of 
Veterinary Antimicrobial Consumption (ESVAC) 
project already collects such data from 29 countries 
across Europe. Its 2014 report, for example, demon- 
strates that 68.4 mg / per population corrected 
unit (PCU) of antibiotics were sold for use in 
food animals in the Netherlands, in the midrange 
of 3.10 mg/PCU (Norway) to 418.8. mg/PCU 
(Spain).3 We believe data for calculating both 
numerator and denominator of this metric also 
are currently available in the U.S. The FDA issues 
annual reports on antibiotic sales for use in food 
producing animals.4 Meanwhile, the USDA collects 
and maintains livestock and poultry production data, 
including the pounds produced,5as well as data on 
imports of meat and poultry products, and in the live 
animals from which those products are derived.6  
An alternate metric, once more 
detailed data are available
A more desirable metric for reporting antibiotic 
use information in the U.S. would be one based 
on animal defined daily dose7, a numerical measure 
of drug consumption that indicates the daily 
maintenance dose needed for a particular use and 
active ingredient in a particular species (and age 
group, if relevant). This metric already is widely used 
within the European Union; its adoption by the 
U.S. would allow for the future comparison of the 
U.S. and other important food animal-producing 
countries. Its use in the U.S. would first require 
collection of detailed and comprehensive antibiotic 
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use data down to the farm level that is not currently done in the U.S., nor is yet under consideration. There 
are several advantages to using this metric, rather than mg/PCU.  
This second metric adds another layer of important information – namely, the potency of the particular 
antibiotic used is built into the metric.8 This metric also can facilitate the comparison of trends in antibiotic 
use over time, even if the potency of the antibiotics used varies over that time period.9 Finally, it allows for a 
more meaningful comparison of antibiotic use in food animal production and in human medicine. Different 
European entities use variations on this second metric that differ depending on the methodologies used to 
calculate them (see Table A).10   
Table A:  Variations on an Animal Defined Daily Dose metric. 
  Metric         Explanation Metric 
used in
ADD
DK 
Animal Daily Dose 
(Denmark)
The ADD
DK
 is the assumed average maintenance dose needed 
to treat one kilogram of animal during one day for the main 
indication in the target species, in accordance with Denmark’s 
authorizing document for that product.1
DANMAP,  
2009-2011
DADD
DK
  
Defined Animal Daily 
Dose (Denmark)  
The DADD
DK
 is specified for a particular animal species. It 
is the average maintenance dose (in mg/kg) per day for a 
drug used for its main indication in the appropriate animal 
species.12 The DADD
D
K is not defined at product level but for 
each antibiotic agent, administration route and animal species 
and when appropriate, also age group.
DANMAP,  
2012 - present
DDDA
NAT
  
Defined Daily Dose 
Animal (Netherlands) 
Based on national antibiotic usage data, the ‘Defined Daily 
Dose Animal’ is a metric used to determine the amount of 
antibiotics used within a particular livestock sector, irrespective 
of any differences between farms in the sector; it is expressed 
as DDDA/animal year.13 The DDDANAT is determined 
by first calculating the total number of treatable kilograms 
within a particular livestock sector for a specific year, and then 
dividing this number by the average number of kilograms of 
animal present within that sector. 
Maran/
NethMAP 
Reports
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Appendix B:  Tools for Health 
Professionals To Improve Use of 
Medically Important Antibiotics in 
Livestock
Health professionals, their institutions and 
professional organizations are on the front lines of 
the antibiotic resistance crisis. Each should be fully 
committed to antibiotic stewardship to preserve the 
effectiveness of existing antibiotics for as long as 
possible, and ultimately to better protect the public 
against rising rates of antibiotic resistant infections.  
Healthcare professionals around the world are 
leading antibiotic stewardship efforts in hospitals 
and outpatient settings. There is also an opportunity 
for health leaders to help end the overuse and 
misuse of antibiotics in food animal production. 
Of all medically important antibiotics sold for 
use in the U.S., 70% of them go to food animals, 
not people. Most of those antibiotics are mass-
administered to groups of animals where there is 
neither a diagnosed disease, nor a working diagnosis. 
Antibiotics are routinely fed to flocks and herds as a 
quick fix, often in place of better hygiene, nutrition, 
animal husbandry or management practices – all of 
which can help prevent the need for antibiotics in 
the first place.  
In May 2017, a panel of experts in human 
and veterinary medicine, infectious diseases, 
epidemiology, public health and microbiology 
issued a Policy Roadmap to Reduce Antibiotic 
Use in Livestock http://battlesuperbugs.com/
PolicyRoadtrip. While the recommendations in 
the document mainly pertain to leadership needed 
from state and federal policymakers, there also is 
much that can be accomplished by clinicians, their 
professional groups and institutions.
Using Existing Toolkits
A toolkit1 recently released by the Clinician 
Champions in Comprehensive Antibiotic 
Stewardship (CCCAS) collaborative – a joint 
initiative of the Pediatric Infectious Diseases Society 
(PIDS), Sharing Antimicrobial Reports for Pediatric 
Stewardship (SHARPS), the Pediatric Infectious 
Diseases Society (PIDS) and Health Care Without 
Harm (HCWH) – specifically addresses the role 
of clinicians and healthcare facilities in promoting 
comprehensive stewardship of antibiotics in both 
food production and clinical practice alike. It states: 
“It is imperative that antibiotic stewardship 
programs seeking to preserve the effectiveness of 
existing antibiotics in human health also consider 
strategies that reduce overuse of antibiotics in the 
agricultural sector. This module provides the tools 
to incorporate this important aspect of stewardship 
into your program. In addition to bringing this to 
the forefront of hospital- based care, we aim for 
this comprehensive approach to translate to the 
community setting as well, via patient education in 
ambulatory settings.” 
Here we highlight just a few of the strategies 
and resources covered by that Toolkit.  They 
track some of the seven core elements of successful 
antibiotic stewardship programs outlined by the 
CDC2. Committed Leadership; Accountability; 
Drug Expertise; Action; Tracking; Reporting; and 
Education. 
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Next Steps for Hospitals, Health Organizations, Health Professional Groups 
Leadership Commitment 
Make a strong statement by your institution in support of antibiotic stewardship that includes the 
phase-out of medically important antibiotics being routinely used in food animal production, and the 
importance of health organizations and facilities making purchasing decisions consistent with that goal. 
Action, beyond your facility 
Endorse hospitals associations, medical schools and universities making their own statements to support 
phase-out of medically important antibiotics for routine use in food animals. 
Expand your modeling and leadership of antibiotic stewardship organization-wide by passing policy 
guiding your procurement of meat and poultry products. 
Next Steps: Individual Champions for Antibiotic Stewardship 
Nurture Committed Leadership 
Be prepared to explain to your leadership why buying meat raised where medically important antibiotics 
have not been routine used is clinically relevant, doable and important. 
Make sure you know which antibiotics are used in food animal production, and be familiar with 
mechanisms of plasmid transferability, cross-selection and co-selection, so as to explain how antibiotic use 
on farms can spur development and spread of resistance to antibiotics from both related and unrelated 
classes.
To make your best case, anticipate questions about costs, and options for forward steps. The CCCAS Toolkit 
links to such presentations. 
Accountability / Expertise 
All health professionals should: 
Embrace a One Health approach to antibiotic resistance, meaning that misuse or inappropriate use of 
medically important antibiotics, whatever the setting, is a shared responsibility. 
Hold your profession responsible for making antibiotic resistance, and the fight to keep antibiotics effective, a 
priority policy, especially including taking strong policy positions on antibiotic use in non-human settings. 
Hold yourself accountable for understanding how the meat and other food products served in your facility, 
or at your lunches, meetings and conferences, is purchased. 
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For those leading Antibiotic Stewardship Programs (ASPs):
Incorporate strategies to reduce antibiotic use in food animal production into your ASPs. 
Invite facility food service leaders and dietitians onto your antibiotic stewardship team. 
Action 
Help draft and be a champion for your hospital/clinic, institution, or professional society to pass a policy 
resolution to phase-out the procurement of meat and poultry produced with the routine use of medically 
important antibiotics, perhaps modeled on the following draft. 
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DRAFT Resolution
Ending Medically Important Antibiotic Use for Routine Disease Prevention
SUBJECT:  No Routine Use of Antibiotics Important to Human Medicine in Food Animal Production 
INTRODUCED BY: 
WHEREAS, the World Health Organization warns that unless we act urgently, the world will enter a ‘post-
antibiotic era’ where even common infections will again kill patients3;
WHEREAS, The Centers for Disease Control and Prevention (CDC) estimates conservatively at least 23,000 
patients in the U.S. already die each year from antibiotic‒resistant infections4;
WHEREAS, Antibiotic use and overuse are principal drivers for the emergence and spread of antibiotic resistance;
WHEREAS, Of all U.S. sales of medically important antibiotics (e.g. those from classes important to disease 
treatment in humans), about 70% are products for use in food animals, and the remainder for use in human 
medicine, according to the Food and Drug Administration (FDA)5;
WHEREAS, The FDA’s National Antibiotics Resistance Monitoring System reports that antibiotic-resistant 
bacteria have become a common fixture in retail meat6;
WHEREAS, An ever-larger, but already compelling body of evidence demonstrates that this large-scale use of 
medically important antibiotics in food animals contributes to the development and spread antibiotic resistance, 
including to human populations7;
WHEREAS, In January 2017, and after approximately seven decades of use, the FDA finally effected the end of 
medically important antibiotics being mass-administered to flocks and herds in animal feed or water, specifically 
for the purposes of growth promotion or increased feed efficiency8;  
WHEREAS, FDA continues to allow the routine administration of medically important antibiotics to flocks and 
herds for ‘disease prevention’ in the absence of a disease diagnosis, and at dosages identical or similar to those used 
for growth promotion.9
WHEREAS, Improved collection and public reporting of data on sales of antibiotics for use in agriculture – 
including parsed out data to illuminate in which animal species and for what particular purpose such antibiotics 
are used – is fundamental to efforts by health officials and researchers to both better understand development and 
spread of antimicrobial resistance, and to assess the efficacy of any steps taken to address it.  
Be it resolved that:  Our [insert your professional organization] supports federal and state efforts to phase-out or 
ban routine or regular addition of antibiotics to animal feed or water for the purpose of disease prevention.
Be it resolved that:  Our [insert your professional organization] recognizes that to model antibiotic stewardship, 
and to do our part to help keep existing antibiotics more effective for longer, it’s important to set a goal of 
purchasing meat and poultry products from operations that only allow use of medically important antibiotics for 
animals that are sick with diagnosed disease, and never mass administered to herds or flocks for [routine] disease 
prevention.   
56
Combating Antibiotic Resistance:  
A Policy Roadmap to Reduce Use of Medically Important Antibiotics in Livestock
Endnotes 
1  Pediatric Infectious Disease Society and Health Care Without Harm. Antimicrobial Stewardship through Food 
Animal Agriculture Toolkit Module. March 2017. https://noharm-uscanada.org/sites/default/files/documents-
files/4603/CCCAS%20Toolkit%20Module_FINAL_3-2-2017.pdf.  Accessed February 28, 2017. 
2  Core Elements of Hospital Antibiotic Stewardship Programs. Centers for Disease Control and Prevention.  May 25, 
2016. https://www.cdc.gov/getsmart/healthcare/implementation/core-elements.html.  Accessed February 28, 2017.
3  World Health Organization Press Release. 2014. http://www.who.int/mediacentre/news/releases/2014/amr-
report/en/.  Accessed May 1, 2017. 
4  CDC. Antibiotic Resistance Threats in the United States. 2013.  http://www.cdc.gov/drugresistance/threat-
report-2013/pdf/ar-threats-2013-508.pdf.  Accessed March 9, 2017. 
5  Record-High Antibiotic Sales for Meat and Poultry Production. The Pew Charitable Trusts. 2013. http://
www.pewtrusts.org/en/multimedia/data-visualizations/2013/recordhigh-antibiotic-sales-for-meat-and-poultry-
production.  Accessed March 16, 2017; 2011 Summary Report on Antimicrobials Sold or Distributed for Use in 
Food-Producing Animals. U.S. Food and Drug Administration. 2017. www.fda.gov/downloads/ForIndustry/UserFees/
AnimalDrugUserFeeActADUFA/UCM338170.pdf.  Accessed February 28, 2017; Food and Drug Administration 
Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology. Drug Use Review. April 5, 2012. 
www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM319435.pdf.  Accessed February 28, 
2017. 
6  U.S. Food and Drug Administration, National Antimicrobial Resistance Monitoring System. 2014 NARMS 
Integrated Report. 2016. https://www.fda.gov/AnimalVeterinary/SafetyHealth/AntimicrobialResistance/
NationalAntimicrobialResistanceMonitoringSystem/ucm059103.htm.  Accessed July 07, 2017. 
7  Expert Commission on Addressing the Contribution of Livestock to the Antibiotic Resistance Crisis. Combating 
Antibiotic Resistance:  A Policy Roadmap to Reduce Use of Medically Important Antibiotics in Livestock. 2017. 
Washington, D.C. http://battlesuperbugs.com/PolicyRoadmap.  Accessed August 19, 2017. 
8  FDA Announces Implementation of GFI #213, Outlines Continuing Efforts to Address Antimicrobial Resistance. 
U.S. Food and Drug Administration . 2017. https://www.fda.gov/AnimalVeterinary/NewsEvents/CVMUpdates/
ucm535154.htm.  Accessed May 1, 2017. 
9  Expert Commission on Addressing the Contribution of Livestock to the Antibiotic Resistance Crisis. Combating 
Antibiotic Resistance:  A Policy Roadmap to Reduce Use of Medically Important Antibiotics in Livestock. 2017. 
Washington, D.C. http://battlesuperbugs.com/PolicyRoadmap.  Accessed August 19, 2017. 
57
Appendix C:   Tools for State and Local Governments to Improve Use of 
Medically Important Antibiotics in Livestock
While federal action is important in order to make progress on reducing unnecessary antibiotic use and 
addressing antibiotic resistance, many other actors have essential roles to play, particularly when it comes to 
uses of the drugs in food animal production. State and local governments can take considerable action to 
ensure that antibiotics are not overused in the livestock sector. 
State action can move the market and drive improved antibiotic use practices while reducing risk for their 
citizens, demonstrating the feasibility of alternative approaches, and laying the groundwork for eventual 
action at the national level. California has shown early leadership on the issue, passing legislation to curtail 
the routine use of antibiotics and institute monitoring of antibiotic use and sales.  
In addition to laws that address how antibiotics are used, state and local actors can also make procurement 
choices to prioritize and increase the purchase of meat and poultry raised without the routine use of 
antibiotics in the absence of diagnosed disease and support producers that are using antibiotics responsibly. 
The California Model: Legislation1 to Reduce and Monitor Livestock Antibiotic Use 
California provides a model for other states to draw on for their own efforts to reduce unnecessary use of 
medically important antibiotics in food animal production. Key features of California’s legislation include: 
Requires veterinary authorization for use of medically important antibiotics. 
Prohibits routine disease prevention use of medically important antibiotics. 
Allows use for: 
-   Treatment of sick animals; 
-   When necessary for surgery or medical procedures; 
-   To control the spread of disease outbreaks; or 
-   For prophylaxis to address an elevated risk of contraction of particular 
     disease or infection (as long as the use does not constitute a “regular pattern of use”
Requires the California Department of Food and Agriculture to monitor sales and usage to help 
producers improve antibiotic use practices
Requires the development of guidance on antimicrobial stewardship to help producers improve  
antibiotic use practices 
Requires a report to the legislature on progress made 
Other Options for State Action to Reduce Livestock Antibiotic Use 
Establish targets for reducing the sale or use of antibiotics in food-producing animals in the state 
(e.g. a 50% reduction relative to a benchmark year). 
Phase out all use in food-producing animals of certain antibiotics that are critically important to 
human medicine. 
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Procurement by State and Local Government Agencies 
States and local governments could set targets for procurement of meat and poultry produced without 
the routine use of antibiotics. A large portion of the chicken industry has already made commitments to 
eliminate the routine use of medically important antibiotics and progress towards those commitments. State 
and local governments could prioritize meat and poultry purchases from producers with such commitments, 
particularly those that adhere to third-party verified standards such as the Certified Responsible Antibiotic 
Use (CRAU) (add link) standard for poultry or otherwise require that the suppliers refrain from the use 
of medically important antibiotics for growth promotion and prevention. Other standards and claims with 
strong antibiotic use provisions include Organic, Humane Certified, Animal Welfare Approved, Raised 
Without Antibiotics (Process Verified Program), and Global Animal Partnership (GAP). 
State or Local Legislation on Reporting of Antibiotic Use Practices in Meat Supply Chain 
States or cities also could enact legislation to require grocery stores in their jurisdictions to report to the city 
or state the antibiotic use practices associated with the meat or poultry they sell. The city or state could then 
analyze this data and make information and guidance available to the public. 
Endnotes 
1  A copy of the bill, Senate Bill 27 (SB 27), is available here: http://leginfo.legislature.ca.gov/faces/billNavClient.
xhtml?bill_id=201520160SB27. The bill also bans growth promotion use of medically important antibiotics, but that 
simply replicates FDA regulations.
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Appendix D: Tools for Restaurants, Food Retailers and Food 
Management Companies to Improve Antibiotics Use in their Meat and 
Poultry Supply Chains
Consumer demand for meat and poultry raised with responsible antibiotics use practices continues to rise. 
People are rightfully concerned that antibiotic overuse in livestock and poultry exacerbates the public health 
crises of antibiotic resistance. By preferentially choosing meat raised with responsible antibiotic practices, the 
public is sending a clear signal to the livestock industry that they need to reform current practices. Major 
buyers of meat and poultry are sending a similar signal to the livestock industry.  The 2016 Chain Reaction II 
Antibiotics Scorecard, released by several NGO groups, ranked the antibiotic policies and practices of the top 
25 restaurants in the United States.1 Nine of 25 chains earned passing grades, thanks in large part to strong 
policies for chicken supplies.  The number of companies with passing grades doubled from 2015 to 2016. 
Similarly, leading health systems throughout the U.S. have set impressive goals around responsible meat and 
poultry procurement; in some cases, up to 60% of a health system’s purchases are comprised of meat raised 
without routine use of antibiotics.2,3 
The good news for major buyers throughout the food sector is that availability of supply is growing to meet 
demand, especially in the chicken industry. Major chicken suppliers like Tyson, Perdue, and Foster Farms have 
either made commitments to phase out routine antibiotics use of medically important antibiotics in their 
supply chains or have already done so.4,5,6 Pilgrim’s Pride committed 25% of its vast chicken supply to be 
raised without antibiotics by 2020.7 
There are signs of progress in the pork industry as well. Since 2016, Smithfield (the largest pork producer 
and processor in the world) and Tyson have launched product lines of raised-without-antibiotics pork that 
are meant for retail and food service sectors.8,9  Positive signs are also beginning to emerge from the beef 
industry: Cargill announced in April 2016 that it would cut its use of medically important antibiotics by 20% 
in 1.2 million cattle.10  This is a virtuous cycle: the more consumers, foodservice, and institutional buyers ask 
for responsibly raised meat, the more the industry responds. 
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1. A time-bound commitment to phase out routine use of medically-important antibiotics, i.e. for disease
prevention; use of antibiotics for treatment of sick animals or to control identified disease outbreaks need
not be limited.
2. A requirement that production claims be verified by a 3rd-party auditor to provide assurance that 
antibiotics use practices match company policies.  Verified standards  and claims with strong antibiotics 
use provisions include the Certified Responsible Antibiotic Use (CRAU) standard for poultry; Certified 
Organic; Certified Humane; Animal Welfare Approved; Raised Without Antibiotics or No Antibiotics 
Ever (if compliant with USDA Process Verified Program), and Global Animal Partnership.11,12,13,14,15,16   A 
producer could also work with the USDA to develop a company-specific Process Verified Program that 
complies with an antibiotics policy that bans medically important antibiotics for growth promotion and 
routine disease prevention uses.
3. A publicly available, annually updated progress report to ensure that customers and investors (if
applicable) are informed.
We also encourage institutional and foodservice purchasers to do the following: 
 1. Ask their meat and poultry suppliers about their antibiotic use practices to improve transparency
about which antibiotics are being used by supplying farms, in what quantities, and for what
species. Even if this information is kept confidential, it sends an important signal to producers. 
2. Engage in public policy to contribute to solutions at federal, state and local levels.
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Responsible Antibiotics Use Procurement Toolkit 
We encourage all major buyers – whether at a grocery chain, a restaurant, or a foodservice operation – to 
set clear antibiotic use policies governing meat and poultry procurement decisions at their company, school, 
and/or hospital. These policies should have three key components and be integrated into bidding processes 
and contracts:
Endnotes 
1   2016 Chain Reaction Antibiotics Scorecard (NRDC.org): https://www.nrdc.org/resources/chain-reaction-how-top-
restaurants-rate-reducing-antibiotics-their-meat-supply 
2   Health Care Sector Demands Sustainable Meat and Poultry (Health Care without Harm): https://noharm-uscanada.
org/articles/press-release/us-canada/health-care-sector-demands-sustainable-meat-and-poultry 
3   Extensive information for major buyers in the health-care sector interested in purchasing meat and poultry raised 
without routine antibiotics is available via Health Care Without Harm: https://noharm-uscanada.org/purchasing 
4   Antibiotic Use –Statement (Tyson Foods): http://www.tysonfoods.com/media/position-statements/antibiotic-use.aspx 
5   Antibiotics Position Statement (Perdue Farms): https://www.perdue.com/perdue-way/no-antibiotics/
6   Antibiotics Stewardship Statement (Foster Farms):  https://www.fosterfarms.com/because-we-care/antibiotic-
stewardship/ 
7   Pilgrim’s Expects 25% of Its Chicken Will Be Antibiotic-Free by 2019 (Wall Street Journal): https://www.wsj.com/
articles/pilgrims-expects-25-of-its-chicken-will-be-antibiotic-free-by-2019-1429564675 
8   Smithfield Foods Introduces Pure Farms™ Antibiotic-Free Product Line (Smithfield Foods): http://www.
smithfieldfoods.com/newsroom/press-releases-and-news/smithfield-foods-introduces-pure-farms8482-antibiotic-free-
product-line 
9   Cleaner Meat; Just months after Big Pork said it couldn’t be done, Tyson is raising up to a million pigs without 
antibiotics (Quartz.com): https://qz.com/624270/just-months-after-big-pork-said-it-couldnt-be-done-tyson-is-raising-
up-to-a-million-pigs-without-antibiotics/ 
10   Cargill eliminates 20% of shared-class antibiotics used for beef cattle (Cargill.com): https://www.cargill.com/news/
releases/2016/NA31934263.jsp 
11   Certified Responsible Antibiotic Use (CRAU).Poultry that supports health from farm to fork (BattleSuperbugs.org): 
http://battlesuperbugs.com/crau-standard 
12   Animal Welfare Approved: https://animalwelfareapproved.us/ 
13   National Organic Program. United States Department of Agriculture (USDA.gov) https://www.ams.usda.gov/about-
ams/programs-offices/national-organic-program 
14   Certified Humane: http://certifiedhumane.org/ 
15   Official Listing of Approved USDA Process Verified Programs (USDA.org): https://www.ams.usda.gov/sites/default/
files/media/Official%20ListingPVP.pdf 
16   Global Animal Partnership: http://www.globalanimalpartnership.org/
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Appendix E:  Policies Leading to Reduced Antibiotic Use in Two 
Countries 
Denmark and the Netherlands are two European livestock-producing countries that have made significant 
efforts to reduce antibiotic* use in the production of food animals.  Both countries have robust and 
profitable livestock sectors. They offer many lessons for the U.S. to draw upon in its own efforts to reduce 
antibiotic use in food animal production. 
Denmark 
Denmark (along with Sweden and Norway) emerged as an early model for how the adoption of new 
policies and practices could quickly and effectively reduce use of antibiotics in food animal production. 
Establishment of DANMAP 
The establishment of DANMAP, the Danish Integrated Antimicrobial Resistance Monitoring and Research 
Programme, in 1995 provided a platform to document the effect of different actions taken. Figure 1, for 
example, shows the impact of declining avoparcin use on the prevalence of avoparcin/vancomycin-resistant 
Enterococcus faecium in Danish broilers.1  
Figure 1. Avoparcin consumption and resistance (%) to avoparcin/vancomycin in E. faecium from broilers. 
Similarly, Figure 2 shows that total antibiotic consumption in animals in Denmark, relative to 1994 levels, 
dropped 43% by 2013 and 47% by 2015. Meanwhile, the number of pigs produced rose 15% from 1994 to 
2015.25
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Figure 2. Antibiotic consumption and millions of pigs produced in Denmark, 1994-2015.
Data collection on veterinary use of antibiotics 
As stated, DANMAP collects data on veterinary use of antibiotics. In Denmark, antibiotics are prescription-
only drugs. By law, veterinarians are required to report each month on all prescriptions written and drugs 
used for production animals to the VETSTAT database26; for most of them, the registration of data is 
automatically linked to their writing of invoices. In addition to veterinary drug sales, data also are sent 
electronically from pharmacies, private companies and feed mills to VETSTAT. For each prescribed item, 
VETSTAT holds detailed information about its source and consumption, its date of sale, the prescribing 
veterinarian, source ID (identity of the pharmacy, feed mill, or veterinarian practice reporting), package 
identity code and amount, animal species, age-group, disease category and code for farm-identity (Central 
Husbandry Register).27 At pharmacies, the electronic registration of sales data is linked to stock reports and 
the billing process, ensuring the data are accurate with respect to the identity and amounts of antibiotics 
listed there.  
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1995 DANMAP is created to research/monitor antibiotic use and resistance in humans, animals, food.
1995 Government bans growth promotion use of avoparcin.
1996
Pharmacies and the pharmaceutical industry are barred from increasing sales by offering economic 
incentives to veterinarians or others.
1998 
Government bans growth promotion use of virginiamycin.  
The EU bans growth promotion uses of virginiamycin, bacitracin, tylosin, spiramycin.
2000
VETSTAT database established to record (by animal age group, herd and veterinarian) all antibiotics 
prescribed for production animals. 
2002 Fluoroquinolones intended for injection are restricted to use by veterinarians only.
2002 EU extends its earlier growth promotion ban to all antibiotics. Effective 2006.
2003
Mandatory susceptibility testing that documents the need for fluoroquinolones prior to their use in 
production animals, and mandatory notification of authorities with that use as well. 
2005 
Action plan issued for reducing swine antibiotic use, including development of swine prudent use 
guidelines, and outreach to veterinarians with a high prescription rate.
2007
Action plan issued for also reducing antibiotics in cattle and poultry, including: (1) new treatment 
guidelines; (2) biennial audit of veterinarians; and, (3) new oversight to ensure no financial conflicts 
of interest between antibiotic makers and veterinarians.
2010
“Yellow card” control of antibiotic use begins in pig production, imposing preventive measures in 
the herds with highest consumption per pig. 
2010 Use of cephalosporins in pig production is voluntarily ended.
2010 Evidence-based treatment guidelines are issued for swine veterinarians.
2010 Joint AMR action plan established by Ministries of Health, Food and Agriculture.
2010
One veterinarian/one farmer herd health agreements are mandated for swine and cattle,  
with an emphasis on welfare and disease prevention not using antibiotics.
2010 Thresholds are established for antibiotic use, mortality and welfare parameters in swine, cattle.
2014 Differentiated taxes implemented on antibiotics for veterinary use.
2014 New and tighter rules on antibiotic treatment of groups of pigs.
2015 Action plan to control livestock-associated MRSA in pigs. 
2016
“Yellow card” controls are differentiated to focus on prevention of fluoroquinolones and 
cephalosporins use, and on limiting tetracycline use in pig production.
Box A: Timeline of select Danish initiatives
Pre-1970s All veterinary medical products are made available only by prescription.
1994 Central Husbandry Register is created to register and identify all herds.
1994/95 Prophylactic antibiotic use is prohibited.
1995 Veterinarian profits directly from sales of prescribed drugs are limited to 5-10% of income.
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Danish initiative 
Over the years, many initiatives have been 
undertaken in Denmark to reduce veterinary use of 
antibiotics while maintaining a high level of animal 
production and welfare. Close cooperation between 
Denmark’s scientists and policymakers, as well as the 
Danish livestock industry, allowed new initiatives to 
be continuously developed and implemented that 
further reduced antibiotic use.  
Box A lists the initiatives by both governmental 
interventions and voluntary actions taken by 
industry. In brief, they include a ban on the use of 
antibiotics that are critically important to human 
medicine and measures to remove incentives for 
farmers and veterinarians to use antibiotics as a 
management tool. While some initiatives have 
been evidence-based, others were grounded 
more in common sense – sometimes necessary to 
expeditiously address new problems. Though some 
of the biggest changes in food animal production 
took place two decades ago, the industries continue 
to thrive. Denmark exports 60% of its poultry 
meat28, and remains among the top three pork-
exporting nations in the European Union.29 
Yellow card initiative 
Denmark’s enhanced surveillance of both antibiotic 
use and resistance in its pig production also 
facilitated implementation of a warning (yellow 
card) system. In 2005, large differences in antibiotic 
use on farms were observed in VETSTAT. As a 
result, authorities adopted treatment guidelines and 
began auditing prescription patterns and usage.30 
These measures eventually led to a yellow card 
initiative targeting the pig producers with the 
highest use of antibiotics. Pig producers found 
to be using antibiotics above one or more of the 
government-established thresholds within a nine-
month period face penalties that include limitations 
on usage and/or storage of antibiotics, unannounced 
inspections and increased veterinary supervision. A 
pig producer may be required to reduce stocking 
density, but only in the case of continued excessive 
use of antibiotics.31 Using the yellow card system, 
Denmark has lowered overall antibiotic use by 
iteratively setting new thresholds, and then targeting 
top antibiotic users. 
The Netherlands
Before 2008, high antibiotic use in the Netherlands’ 
livestock sector persisted, despite an earlier end to 
antibiotic use for growth promotion (See Figure 3)32. 
Combined with public concern about the potential 
for drug-resistant bacteria to spread from animals to 
people, the persistently high usage led to additional 
measures described in Box B, and instituted after 
2008.33 These latter measures (See Box B) succeeded 
in greatly reducing overall antibiotic use in the 
sector (Figure 4). 
Figure 3:  Persistence of sales of antibiotics (in tons 
of active substances) in the Netherlands  
before and after a 2006 ban on antibiotic growth 
promoters (AMGPs) (adapted)  
* Therapeutic use included antibiotics for treatment, control
and prevention until 2011, after which prevention uses 
were no longer allowed. 
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Because the Netherlands had successfully controlled 
MRSA in hospitals through strict measures, reports 
in 2005 of widespread livestock-associated MRSA 
in pigs – and their potential transmission to livestock 
workers – caused immediate concern.34 A multi-
stakeholder task force was then formed to reduce 
antibiotic use in food animal production.35 Officials 
felt additional pressure after retail poultry was 
discovered to be widely contaminated with bacteria 
producing extended-spectrum beta-lactamase 
(ESBL) enzyme. These bacteria were also potentially 
linked to the death of a Dutch patient.36
The ESBL enzyme breaks down commonly used 
antibiotics making the bacteria producing the 
enzyme resistant to treatment by the affected 
antibiotics.  
Policies and framework 
Setting targets. Using 2009 as a baseline, the 
government set clear targets for reducing antibiotic 
use in livestock production as a whole: 20% by 
2011, and 50% by 2013. Both of these targets were 
agreed to by the animal sector. In 2012, a reduction 
target of 70% by 2015 was set by government decree 
without agreement by the animal sector.37 
Public-private partnership. The program in the 
Netherlands has been set up as a public-private 
partnership. Stakeholders in pig, broiler, veal 
and cattle production, along with the Royal 
Netherlands Veterinary Association (KNMvD), took 
responsibility for putting in place effective measures, 
while the national government provided facilitation, 
legislation and inspection. Implementation plans 
for meeting the above targets, for example, were 
developed by the industry members.  
Surveillance of antibiotic usage. Various livestock 
sectors collect data on antibiotic use from 40,000 
farms, anonymize it to protect the identity of 
individuals, and then share it with the independent 
Netherlands Veterinary Medicines Authority (SDa). 
The SDa, the government and the public have 
access only to the anonymized data. An independent 
panel of experts from medicine, veterinary science, 
epidemiology and pharmacy, convened by the SDa, 
analyzes these data and prepares annual reports on 
antibiotic use, the most recent being from 2016.38  
Veterinary oversight. Farms must have only one 
veterinarian per herd, who does periodic inspections 
and who must prescribe any antibiotics administered. 
Generally, the veterinarian inspects and assesses the 
farm before doing so, except in very well-defined 
instances. Farms also must have herd treatment and 
health plans (mostly including resistance profiling 
of the farm and tailored management practices) in 
place. Antibiotics are tiered for farm use according 
to their importance to human medicine. Farms 
are allowed to treat up to 15% of their animals 
using so-called first choice, non-critical antibiotics, 
based on the yearly veterinary consultation and the 
development of the aforementioned farm treatment 
plan that includes treatment protocols for common 
diseases on a particular farm. The second and third 
tiers include certain critical drugs that may only be 
administered by the consulting veterinarian.39 Third-
tier antibiotics (e.g. fluoroquinolones and 3rd and 4th 
generation cephalosporins) also are only allowed if 
susceptibility testing has demonstrated there to be no 
available alternative antibiotic, and are typically not 
used for herd or flock treatment. This tiering system 
also applies to antibiotic use in pets.
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Benchmarking and Transparency. Critical to the program’s success has been establishing and clearly
communicating expectations. The goal of improved herd health is made clear, as are expected responsibilities 
in antibiotic delivery and herd management. The independent panel of experts advising SDa proposes 
veterinary benchmarks regarding the quantity of antibiotics to be used within each livestock (sub)sector. SDa 
can then make comparisons between data collected from farms and veterinarians, although those data have 
been anonymized. A 2014 SDA report, for example, contains the first analysis of prescription patterns by 
Dutch veterinarians.40  
Surveillance of antibiotic resistance. MARAN (the Monitoring of Antibiotic Resistance and Antibiotic
Usage in Animals in the Netherlands), the country’s chief program for monitoring antibiotic resistance in 
animals, also tracks resistance trends in animals and retail meat.41 Monitoring programs across the country 
randomly take samples from animals at slaughter; retail samples also are collected from chicken, pork, beef, 
and turkey and other products, and reflect both domestic and imported products. Parallel to MARAN is 
NethMap, which annually publishes yearly trend data for major pathogens affecting humans, based on robust 
antibiotic susceptibility data collected from hospitals and held in the centralized repository, called ISIS-AR. 
Resistance profiles of Enterococci, Salmonella spp., E. coli and Campylobacter spp. in food animals and retail 
meat are presented in the NethMap-MARAN reports.  
Reduction in antibiotic sales and antibiotic resistance 
Figure 4 shows the rapid drop in antibiotic sales (the metric used to measure success) after various measures 
were implemented starting in 2008. By 2012, total sales had dropped 49% relative from the 2009 baseline, 
reaching the target originally set for 2013 a year early. Sales of 3rd and 4th generation cephalosporins, 
antibiotics critically important to human health and also used in animals, dropped more than 90% over the 
same period. By 2016, total sales had shown a further drop of more than 64%, relative to the 2009 baseline. 42 
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Figure 4:   Dutch sales of antibiotic agents, 1999 to 2016. By year and by 1,000s of kg. of active substances 
sold [not including antibiotic growth promoters]43
 
Among the different animal species and four bacterial groups tested, antibiotic resistance has plateaued or 
trended downward in recent years (with the exception of fluoroquinolone resistance in Campylobacter 
spp.).44 These trends coincide with reduced antibiotic use in food animals. See Figures 5 and 6.   
Figure 5:  Trends in resistance (%) of C. jejuni bacteria isolate from broiler chickens and poultry meat in 
the Netherlands 
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Figure 6: Trends in resistance (%) of E. coli isolated from broilers, slaughter pigs, veal calves and dairy cattle 
in the Netherlands. Similar favorable trends have been observed for Enterococci spp. and Salmonella spp. in 
animal samples. (Adapted from MARAN 2016)45
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